

Patrizia Bottoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/204459/publications.pdf>

Version: 2024-02-01

37
papers

1,849
citations

361296

20
h-index

395590

33
g-index

37
all docs

37
docs citations

37
times ranked

3110
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitochondrial Respiratory Complexes as Targets of Drugs: The PPAR Agonist Example. <i>Cells</i> , 2022, 11, 1169.	1.8	5
2	The Tangled Mitochondrial Metabolism in Cancer: An Innovative Pharmacological Approach. <i>Current Medicinal Chemistry</i> , 2020, 27, 2106-2117.	1.2	2
3	Mitochondrial Metabolism in Cancer. A Tangled Topic. Which Role for Proteomics?. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1158, 1-16.	0.8	3
4	Toward the Standardization of Mitochondrial Proteomics: The Italian Mitochondrial Human Proteome Project Initiative. <i>Journal of Proteome Research</i> , 2017, 16, 4319-4329.	1.8	66
5	CRYOGLOBULIN TEST AND CRYOGLOBULINEMIA HEPATITIS C-VIRUS RELATED. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017007.	0.5	13
6	The epithelial-mesenchymal transition in cancer: a potential critical topic for translational proteomic research. <i>Expert Review of Proteomics</i> , 2016, 13, 115-133.	1.3	14
7	The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 229-244.	0.8	130
8	A Critical Approach to Clinical Biochemistry of Chromogranin A. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 317-323.	0.8	3
9	Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 125-143.	0.8	364
10	CA 19-9: Biochemical and Clinical Aspects. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 247-260.	0.8	218
11	Circulating tumour cells and cancer stem cells: A role for proteomics in defining the interrelationships between function, phenotype and differentiation with potential clinical applications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1835, 129-143.	3.3	23
12	Mitochondrial Proteomic Approaches for New Potential Diagnostic and Prognostic Biomarkers in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2012, 942, 423-440.	0.8	11
13	Cancer Stem Cells: An Innovative Therapeutic Approach. , 2012, , 239-266.		0
14	Cancer Stem Cells: Proteomic Approaches for New Potential Diagnostic and Prognostic Biomarkers. , 2012, , 221-238.		0
15	Cancer stem cells: the development of new cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 875-892.	1.4	34
16	The proteomics of cancer stem cells. Potential clinical applications for innovative research in oncology. <i>Proteomics - Clinical Applications</i> , 2011, 5, 590-602.	0.8	9
17	Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy. <i>Proteomics - Clinical Applications</i> , 2010, 4, 143-158.	0.8	33
18	Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks. <i>Current Medicinal Chemistry</i> , 2010, 17, 61-73.	1.2	78

#	ARTICLE	IF	CITATIONS
19	Proteomic profiling of heat shock proteins: An emerging molecular approach with direct pathophysiological and clinical implications. <i>Proteomics - Clinical Applications</i> , 2009, 3, 636-653.	0.8	13
20	A proteomic approach to characterizing ciglitazone-induced cancer cell differentiation in Hep-G2 cell line. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2009, 1794, 615-626.	1.1	15
21	Cellular Respiration and Dedifferentiation. , 2009, , 45-54.		0
22	Mitochondrial Respiration and Differentiation. , 2009, , 93-102.		0
23	Modulation of cancer cell line differentiation: A neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer. <i>Proteomics - Clinical Applications</i> , 2008, 2, 229-237.	0.8	15
24	Glycolytic enzyme inhibitors in cancer treatment. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1533-1545.	1.9	137
25	Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?. <i>PPAR Research</i> , 2008, 2008, 1-10.	1.1	39
26	The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 293, C12-C21.	2.1	147
27	An update on pharmacological approaches to neurodegenerative diseases. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 59-72.	1.9	48
28	Mitochondria, ciglitazone and liver: A neglected interaction in biochemical pharmacology. <i>European Journal of Pharmacology</i> , 2007, 567, 50-58.	1.7	25
29	Aroyl-Pyrrolyl Hydroxyamides: Influence of Pyrrole C4-Phenylacetyl Substitution on Histone Deacetylase Inhibition. <i>ChemMedChem</i> , 2006, 1, 225-237.	1.6	20
30	Exploring the connection unit in the HDAC inhibitor pharmacophore model: Novel uracil-based hydroxamates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4656-4661.	1.0	46
31	A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists. <i>Journal of Cellular and Molecular Medicine</i> , 2005, 9, 462-467.	1.6	11
32	Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 835-846.	1.9	67
33	Mitochondrial Dysfunction by Synthetic Ligands of Peroxisome Proliferator Activated Receptors (PPARs). <i>IUBMB Life</i> , 2004, 56, 477-482.	1.5	29
34	3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2and/or -C4Substitutions on Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1098-1109.	2.9	61
35	Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. <i>Biochemical and Biophysical Research Communications</i> , 2004, 319, 967-973.	1.0	65
36	3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studies. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1351-1359.	2.9	65

#	ARTICLE	IF	CITATIONS
37	Bezafibrate Induces a Mitochondrial Derangement in Human Cell Lines: A PPAR-Independent Mechanism for a Peroxisome Proliferator. <i>Chemical Research in Toxicology</i> , 2003, 16, 1440-1447.	1.7	40